Related Experiment Videos
[Treatment of malignant adrenal cortex carcinoma]
E Andrès1, F Grunenberger, J E Kurtz
1Service de Médecine interne, Hôpital de Hautepierre, CHU de Strasbourg.
Abstract:
UNCOMMON MALIGNANCY: Adrenocortical carcinoma is a very rare malignancy with poor prognosis. Median survival ranges from 12 to 25 months. Most clinicians recommend aggressive surgical management of either local or recurrent and metastatic disease. ANTICORTISOL AGENTS: Mitotane, the most tested agent against inoperable and metastatic adrenocortical carcinoma, procures overall response rates of 20 to 25%, but recent data do not support its use in the adjuvant setting.
Chemotherapy:
The efficacy of cytotoxic chemotherapy is low but new agents or associations (with platinum salts), new concepts (dose-intensification, MDR (the chemoresistance gene) reversing agents) may be useful and five some hope in this difficult disease.
Radiotherapy:
The role of radiation therapy must be developed.